AGP Executive Report
Last update: 12 hours agoCardiovascular Drug Watch: The EMA’s CHMP has issued a positive opinion for NewAmsterdam Pharma’s obicetrapib (Ubeslo®) and the obicetrapib/ezetimibe fixed-dose combo (Evlarco®), based on Phase 3 results, with an EU decision expected in 2H26. Disability Benefits & Travel Rules: The UK DWP is warning PIP claimants that leaving the country for more than four weeks—even for a holiday—can trigger penalties unless they notify the department promptly and report travel details. Healthcare Finance in the Region: Healthcare Holding Schweiz AG has closed CHF 80 million in syndicated financing to support further medtech acquisitions and expansion. Citizenship Test Requirements: The UK says foreign applicants for citizenship or settlement must pass the “Life in the UK Test,” including booking rules, cost, and the 45-minute format. Global Mobility & Health Context: Russia has published the full 2026 list of countries eligible for its unified e-visa, with specific application timing and stay limits.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
